权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Inhibitors to Clostridium perfrigens epsilon toxin

产气荚膜梭菌ε毒素抑制剂

基本信息

批准号：
7244032
负责人：
MARK S MCCLAIN
金额：
$ 14.9万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-06-01 至 2008-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7244032
关键词：
Agriculture Amino Acids Animal Model Bacterial Toxins Binding Biological Assay Brain Edema Cardiac Categories Cell Line Cell Surface Receptors Cell membrane Cells Cloning Clostridium Clostridium perfringens Clostridium perfringens epsilon toxin Complex Development Dominant-Negative Mutation Effectiveness Enterotoxemia Escherichia coli Exposure to Foundations Future Genes Human Kidney Libraries Link Lung Mediating Membrane Mutagenesis Nature Process Protein Region Proteins Recombinants Research Research Proposals Resistance Screening procedure Structure-Activity Relationship Testing Toxin United States Dept. of Health and Human Services base cytotoxic cytotoxicity design high throughput screening in vivo inhibitor/antagonist insertion/deletion mutation insight monomer mutant novel novel therapeutics receptor small molecule three dimensional structure

项目摘要

DESCRIPTION (provided by applicant): The Clostridium perfringens epsilon toxin, a Category B Select Agent, is responsible for a severe, often fatal enterotoxemia characterized by cardiac, pulmonary, kidney, and brain edema. The mechanism by which epsilon toxin acts is incompletely understood. However, it is believed that toxin monomers bind to specific receptors on sensitive cells, assemble into oligomeric complexes, and form pores in the cell membrane. We hypothesize that inhibitors can be prepared that block one or more of these key steps in the process by which the Clostridium perfringens epsilon toxin mediates cytotoxic effects. The specific aims of this proposal are designed to develop inhibitors of epsilon toxin activity by (1) identifying dominant-negative mutants and (2) identifying small molecule inhibitors. In aim 1, amino acid deletions, insertions, and substitutions will be introduced into the gene encoding epsilon toxin, with special emphasis placed on a region of the protein believed to insert into the target cell membrane. Recombinant mutant proteins will be examined for both a lack of cytotoxicity and for the ability to inhibit the cytotoxic activity of wild-type epsilon toxin. Mutants identified in this aim will increase our understanding of the structure-function relationships that govern epsilon toxin activity, will provide insight into the nature of dominant-negative mutant toxins, and identify new therapeutic candidates for countering exposure to epsilon toxin. In aim 2, a high-throughput screen will be used to identify small molecules that inhibit the cytotoxic activity of epsilon toxin. In addition to identifying novel inhibitors, this aim will validate high-throughput assays that may be used in future studies to test additional compounds for the ability to either inhibit toxin activity or mitigate the effects of the toxin. The inhibitors identified in this R21 Exploratory/Developmental proposal will provide the foundation for future studies aimed at optimizing the inhibitory activities, examining the mechanisms of inhibition, and testing the effectiveness of the inhibitors using established animal models.

描述(由申请人提供)：产气荚膜梭菌epsilon毒素是一种B类精选药物，可导致一种严重的、通常是致命的肠毒素血症，其特征是心脏、肺、肾脏和脑水肿。Epsilon毒素的作用机制尚不完全清楚。然而，人们认为毒素单体与敏感细胞上的特定受体结合，组装成低聚复合体，并在细胞膜上形成孔洞。我们假设，在产气荚膜梭菌epsilon毒素介导细胞毒作用的过程中，可以制备出阻断这些关键步骤中的一个或多个步骤的抑制剂。这项建议的具体目的是通过(1)鉴定显性-负性突变体和(2)鉴定小分子抑制剂来开发epsilon毒素活性的抑制剂。在目标1中，编码epsilon毒素的基因将引入氨基酸的缺失、插入和替换，重点放在被认为插入到靶细胞膜的蛋白质区域。将检查重组突变蛋白是否缺乏细胞毒性，以及是否有能力抑制野生型epsilon毒素的细胞毒性活性。在这一目标中发现的突变将增加我们对支配epsilon毒素活性的结构-功能关系的理解，将提供对显性-负性突变毒素的性质的洞察，并找到新的治疗候选药物来对抗epsilon毒素的暴露。在目标2中，将使用高通量筛选来识别抑制epsilon毒素细胞毒活性的小分子。除了确定新的抑制剂外，这一目标还将验证高通量测试，这些测试可用于未来的研究，以测试更多化合物抑制毒素活性或减轻毒素影响的能力。这份R21探索性/开发性提案中确定的抑制剂将为未来旨在优化抑制活性、检测抑制机制并使用已建立的动物模型测试抑制剂的有效性的研究提供基础。